Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Aventis
|
| gptkbp:acquired |
gptkb:Aventis
|
| gptkbp:acquisition |
gptkb:Medi_Gene_AG
Bristol-Myers Squibb's diabetes business |
| gptkbp:ceo |
gptkb:Paul_Hudson
|
| gptkbp:collaborated_with |
gptkb:Sanofi
|
| gptkbp:employees |
around 100,000
|
| gptkbp:founded |
gptkb:2004
|
| gptkbp:headquarters |
gptkb:Paris,_France
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sanofi-Synthélabo
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:operates_in |
over 100 countries
|
| gptkbp:partnerships |
various academic institutions
other pharmaceutical companies |
| gptkbp:products |
vaccines
cardiovascular drugs diabetes treatments central nervous system drugs |
| gptkbp:research_focus |
gptkb:Company
rare diseases vaccines |
| gptkbp:revenue |
€36 billion (2019)
|
| gptkbp:subsidiary |
gptkb:Genzyme
gptkb:Sanofi_Genzyme gptkb:Sanofi_Pasteur |
| gptkbp:website |
www.sanofi.com
|